A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Donnie Wahlberg is officially set to return as Detective Danny Reagan in CBS's upcoming Blue Bloods spinoff Boston Blue, ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Marked down to just $24 for Prime Day, Methylene Blue is one of the most buzzed-about supplement deals available during the ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron is paying Hansoh $80 million upfront for a phase 3-stage GLP-1/GIP agonist the companies believe can hold its own against Lilly’s Zepbound.

The potential acquisition makes Regeneron interesting, but it isn't a reason to buy the stock now. While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed ...

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains May 21, 2025 6:15 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock REGN 6 Comments ...

Regeneron Pharmaceuticals has announced it will acquire 23andMe, the once high-flying consumer DNA testing company, for $256 million through a bankruptcy auction.

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data while continuing genome testing services.